Drugs / Y90
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05620771 Background | Nov 2022 → Jul 2040 expected | hepatocellular carcinoma | Northwestern University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-90 | “Therasphere® (Y-90)” NCT05620771 ↗ |
| Known as | Therasphere | “Therasphere® (Yttrium-90)” NCT05620771 ↗ |
| Known as | Yttrium-90 | “Therasphere® (Yttrium-90)” NCT05620771 ↗ |